When Tricyclic Antidepressants May Be Your Better Option: Revisiting Older Medications for Specific Conditions

Dr. Tracey Marks discusses the often-overlooked utility of tricyclic antidepressants (TCAs) in an era dominated by newer selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs). While SSRIs and SNRIs gained popularity due to their improved tolerability and fewer side effects compared to the original TCAs from the 1950s, Dr. Marks argues that TCAs still hold significant value for specific patient populations and conditions. She highlights that despite their side effect profile, certain TCAs demonstrate superior efficacy for particular presentations of depression and co-occurring disorders, challenging the notion that newer medications are always superior.

The podcast details five key conditions where TCAs may be a better choice. These include melancholic depression, characterized by profound anhedonia, guilt, appetite loss, and psychomotor slowing, where TCAs often outperform SSRIs. Additionally, for depression co-occurring with chronic pain conditions like disc disease or fibromyalgia, amitriptyline and imipramine are noted as effective, sometimes even preferred over SNRIs like duloxetine. Depression with irritable bowel syndrome (IBS) is another area where TCAs, specifically amitriptyline and imipramine, can be beneficial due to the high concentration of serotonin receptors in the gut, which can be aggravated by SSRIs. Clomipramine is singled out for its strong evidence in treating obsessive-compulsive disorder (OCD), especially in more severe cases. Finally, TCAs, particularly the combination of nortriptyline and lithium, are considered the gold standard for preventing relapse after electroconvulsive therapy (ECT).

Dr. Marks provides practical advice for patients and clinicians. She encourages patients who are not achieving full remission with current medications to discuss the possibility of trying a TCA with their doctor, acknowledging that many younger physicians may have limited experience with these older drugs. She also mentions that TCAs are still widely used in lower doses for other conditions such as nerve pain, migraine headaches, and sleep. However, she also emphasizes crucial contraindications and side effects, including the risk of lethality in overdose for first-generation TCAs (making them unsuitable for suicidal patients), orthostatic issues for those with balance problems, and the potential to induce manic episodes in individuals with bipolar disorder.

Ultimately, the episode underscores the importance of individualized treatment in psychiatry, moving beyond a one-size-fits-all approach. By referencing influential studies like the STAR*D trial, which showed only about 67% remission rates with various antidepressant treatments, Dr. Marks reinforces that suboptimal improvement is common and that exploring all available options, including older but effective medications like TCAs, is crucial for achieving better patient outcomes. The discussion serves as a reminder that a comprehensive understanding of psychopharmacology involves appreciating the nuanced strengths and weaknesses of all therapeutic agents.

the original antidepressants came out around the 1950s and were called the tricyclic antidepressants

even though these medications worked they weren't that easy to take

what the research shows is that certain tricyclic antidepressants work better for certain conditions

melancholic depression is a subtype of depression where you lose all ability to enjoy anything have lots of guilt lose your appetite and have early morning awakenings

people with melancholic depression tend to respond better to the tricyclic antidepressants over the ssris

chlomepramine has very good evidence for being more effective in treating ocd

the combination of nortriptyline and lithium is considered to be the gold standard first choice treatment for maintenance after ect

if your doctor trained in the 2000s he or she may not have much experience using them and therefore it may not think of them as options

the star d trial... showed that only about 67 percent of people experience full remission from their depression symptoms with various medication treatments

because of the cardiac effects these medications are not recommended for someone who has suicidal thoughts because they can be lethal in overdose